Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,152Revenue $M218Net Margin (%)0Z-Score0
Enterprise Value $M2,152EPS $0.3Operating Margin %0F-Score0
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %0Quick Ratio0Cash flow > EarningsN
Price/Sales05-y EBITDA Growth Rate %0Current Ratio0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M0ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with SNTS

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNTSJohn Paulson 2014-03-31 Sold Out -0.79%$31.96 - $31.97
($31.97)
$ 31.960%Sold Out0
SNTSMario Gabelli 2014-03-31 Sold Out -0.07%$31.96 - $31.97
($31.97)
$ 31.960%Sold Out0
SNTSJoel Greenblatt 2014-03-31 Sold Out -0.02%$31.96 - $31.97
($31.97)
$ 31.960%Sold Out0
SNTSJohn Paulson 2013-12-31 Buy 0.79%$21.05 - $32.18
($28.12)
$ 31.9614%New holding, 5000000 sh.5,000,000
SNTSMario Gabelli 2013-12-31 Buy 0.07%$21.05 - $32.18
($28.12)
$ 31.9614%New holding, 392700 sh.392,700
SNTSJoel Greenblatt 2013-12-31 Reduce-0.03%$21.05 - $32.18
($28.12)
$ 31.9614%Reduce -62.26%25,257
SNTSJoel Greenblatt 2013-09-30 Buy 0.05%$21.17 - $27.26
($23.84)
$ 31.9634%New holding, 66922 sh.66,922
SNTSGeorge Soros 2011-09-30 Sold Out -0.0013%$2.49 - $3.39
($3.07)
$ 31.96941%Sold Out0
SNTSGeorge Soros 2011-06-30 Add$3.03 - $3.48
($3.22)
$ 31.96892%Add 46.35%28,100
SNTSGeorge Soros 2011-03-31 Buy $3.14 - $3.69
($3.32)
$ 31.96863%New holding, 19200 sh.19,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNTS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SNTS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PROEHL GERALD TPresident & CEO 2013-12-16Sell56,643$31.950.03view
SNYDER KENTDirector 2013-12-16Sell7,500$31.950.03view
DE MEULES JULIE ASr. VP, Human Resources 2013-12-09Sell15,165$31.950.03view
PROEHL GERALD TPresident & CEO 2013-11-15Sell56,644$32.02-0.19view
SNYDER KENTDirector 2013-11-15Sell7,500$32.01-0.16view
DE MEULES JULIE ASr. VP, Human Resources 2013-11-11Sell15,165$31.940.06view
PROEHL GERALD TPresident & CEO 2013-10-15Sell50,000$22.3243.19view
SNYDER KENTDirector 2013-10-15Sell7,500$22.3143.25view
CRAWFORD DEBRA PSr. VP, CFO, Sec'y, Treas 2013-10-10Sell16,614$21.945.94view
DE MEULES JULIE ASr. VP, Human Resources 2013-10-09Sell15,165$21.1451.18view

Press Releases about SNTS :

    Quarterly/Annual Reports about SNTS:

      News about SNTS:

      Articles On GuruFocus.com
      Mario Gabelli Comments on Valassis Communications Apr 30 2014 
      Mario Gabelli Comments on Santarus Inc. Apr 30 2014 
      Mario Gabelli's ABC Fund First Quarter 2014 Letter Apr 30 2014 
      Mario Gabelli’s Top 5 Fourth-Quarter Stock Buys Feb 07 2014 
      comment on SNTS Mar 06 2013 
      comment on SNTS Mar 02 2013 
      Santarus Inc. Reports Operating Results (10-K) Mar 04 2011 
      Santarus Inc. Reports Operating Results (10-Q) Nov 09 2010 
      Santarus Inc. Reports Operating Results (10-Q) Aug 03 2010 
      Santarus Inc. Reports Operating Results (10-Q) May 07 2010 

      More From Other Websites
      Salix Pharmaceuticals Completes Acquisition of Santarus Jan 02 2014
      SANTARUS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Creation of a... Jan 02 2014
      RedHill Biopharma Sells ADS Dec 31 2013
      Pipeline Setback at Can-Fite BioPharma, Shares Down Dec 31 2013
      Santarus Announces Availability of Amended Tender Offer Materials Dec 30 2013
      Santarus Announces Availability of Amended Tender Offer Materials Dec 30 2013
      Durata Progresses with Dalbavancin Dec 27 2013
      Pipeline Update on Aratana Dec 27 2013
      Update on MDCO's Pipeline Dec 27 2013
      Pipeline Update on Santarus Candidate Dec 26 2013
      Update on ARIAD's Iclusig Dec 26 2013
      G-III Apparel Group Set to Join the S&P SmallCap 600 Dec 23 2013
      Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis Dec 23 2013
      Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis Dec 23 2013
      SANTARUS INC Files SEC form 8-K, Other Events Nov 12 2013

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK